Lykos Therapeutics
MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD545—818m (Dealroom.co estimates Jan 2024.)
Remote Oregon (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | $100m | Series A | |
Total Funding | CAD136m |